Robin Patel

Robin Patel


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
ATAaron J. Tande
Aaron J. Tande
RPRobin Patel
Robin Patel
SUMMARY Prosthetic joint infection (PJI) is a tremendous burden for individual patients as well as the global health care industry. While a small minority of joint arthroplasties will become infected, appropriate recognition and management are critical to preserve or restore adequate function and prevent excess morbidity. In this review, we describe the reported risk factors for and clinical manifestations of PJI. We discuss the pathogenesis of PJI and the numerous microorganisms that can cause this devastating infection. The recently proposed consensus definitions of PJI and approaches to accurate diagnosis are reviewed in detail. An overview of the treatment and prevention of this challenging condition is provided.

16 August 2007 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ATAndrej Trampuz
Andrej Trampuz
KPKerryl E. Piper
Kerryl E. Piper
MJMelissa J. Jacobson
Melissa J. Jacobson
AHArlen D. Hanssen
Arlen D. Hanssen
KUKrishnan K. Unni
Krishnan K. Unni
RPRobin Patel
Robin Patel
Culturing of samples of periprosthetic tissue is the standard method used for the microbiologic diagnosis of prosthetic-joint infection, but this method is neither sensitive nor specific. In prosthetic-joint infection, microorganisms are typically present in a biofilm on the surface of the prosthesis. We hypothesized that culturing of samples obtained from the prosthesis would improve the microbiologic diagnosis of prosthetic-joint infection.

20 August 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
JLJose Luis Del Pozo León
Jose Luis Del Pozo León
RPRobin Patel
Robin Patel
A 62-year-old woman with osteoarthritis presents with a 7-month history of progressively worsening left hip pain radiating to the groin, 8 months after undergoing total left-hip arthroplasty. Physical examination reveals a sinus tract overlying her left hip. A radiograph shows loosening of the prosthesis at the bone–cement interface. How should her case be managed?

1 January 2015 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
RPRobin Patel
Robin Patel
Background: First introduced into clinical microbiology laboratories in Europe, MALDI-TOF MS is being rapidly embraced by laboratories around the globe. Although it has multiple applications, its widespread adoption in clinical microbiology relates to its use as an inexpensive, easy, fast, and accurate method for identification of grown bacteria and fungi based on automated analysis of the mass distribution of bacterial proteins in cultured bacteria or fungi. Content: This review provides a historical perspective on this new technology. Modern applications in the clinical microbiology laboratory are reviewed with a focus on the most recent publications in the field. Identification of aerobic and anaerobic bacteria, mycobacteria, and fungi are discussed, as are applications for testing urine samples and positive blood culture bottles. The strengths and limitations of MALDI-TOF MS applications in clinical microbiology are also addressed. Summary: MALDI-TOF MS is a tool for rapid, accurate, and cost-effective identification of cultured bacteria and fungi in clinical microbiology. The technology is automated, high throughput, and applicable to a broad range of common as well as esoteric bacteria and fungi. MALDI-TOF MS is an incontrovertibly beneficial technology for the clinical microbiology laboratory.

1 January 2004 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
PDF file
RPR.M. Prabhu
R.M. Prabhu
RPRobin Patel
Robin Patel

15 March 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
GSGina Suh
Gina Suh
TLthomas patrick lodise
thomas patrick lodise
PTPranita D. Tamma
Pranita D. Tamma
JKJane M. Knisely
Jane M. Knisely
JAJose Alexander
Jose Alexander
FGfor the Antibacterial Resistance Leadership Group
for the Antibacterial Resistance Leadership Group
Increasing antimicrobial resistance and medical device-related infections have led to a renewed interest in phage therapy as an alternative or adjunct to conventional antimicrobials. Expanded access and compassionate use cases have risen exponentially but have varied widely in approach, methodology, clinical situations in which phage therapy might be considered, dosing, route of administration, and outcomes.